James Silverman
@Opaleye Management Inc.
Latest period2024 - Q3ReportedManaged Assets$599.558MTotal holdings44
Assets growth rate37%Assets growth rate (2-Q avg)16.19%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Opaleye Management Inc.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 44 positions.
Assets under management
The assets under management (AUM) of Opaleye Management Inc. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 599.558M in assets, with a quarterly growth rate of 37% and a 2-quarter average growth rate of 16.19%. The portfolio is managed by James Silverman, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
XOMAXoma Corp Del
| 1.11% | $6.62M 250,000 shares@ $26.48 avg price | |
NUVLNuvalent Inc
| 1.1% | $6.547M 64,000 shares@ $102.3 avg price | Increased 7.93% |
NAMSNewamsterdam Pharma Company
| 0.93% | $5.561M 335,000 shares@ $16.6 avg price | Increased 6.35% |
URGNUrogen Pharma Ltd
| 0.86% | $5.132M 404,100 shares@ $12.7 avg price | Decreased -1.91% |
PTGXProtagonist Therapeutics Inc
| 0.79% | $4.725M 105,000 shares@ $45.0 avg price | |
3834⤦Gossamer Bio Inc
| 0.7% | $4.189M 8M shares@ $0.53 avg price | |
CYTKCytokinetics Inc
| 0.67% | $3.976M 75,300 shares@ $52.8 avg price | Decreased -62.06% |
4857⤦Karyopharm Therapeutics Inc
| 0.67% | $3.961M 6M shares@ $0.67 avg price | |
GOSSGossamer Bio Inc
| 0.62% | $3.706M 3.665M shares@ $1.02 avg price | Decreased -6.26% |
ZNTLZentalis Pharmaceuticals Inc
| 0.6% | $3.559M 967,000 shares@ $3.68 avg price | New Position |